Dianthus Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Dianthus Therapeutics generated cash of -$36,861,000, which is less than the previous year. Cash used in financing activities reached the amount of $133,574,000 last year. Net change in cash is therefore $116,966,000.
Cash Flow
| 2016 | -6.52M | -139K | 10.71M |
|---|---|---|---|
| 2017 | -22.26M | -2.19M | 71.48M |
| 2018 | -41.88M | -91.70M | 142.14M |
| 2019 | -57.10M | 1.53M | 62.29M |
| 2020 | -64.02M | -10.63M | 67.73M |
| 2021 | -9.90M | -33K | 14.91M |
| 2022 | -29.07M | -59.81M | 96.67M |
| 2023 | -36.86M | 20.25M | 133.57M |
DNTH Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 15.42M | 7.63M | 2.66M | 65.07M | 58.34M | 51.56M | 4.54M | 500K |
Operating activities | ||||||||
Net income | -43.55M | -28.47M | -13.10M | -74.93M | -76.76M | -57.51M | -35.49M | -9.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 355K | 147K | 2.02M | 1.97M | 1.84M | 875K | 376K | 6K |
Stock-based compensation expense | 2.9M | 1.51M | 63K | 0 | 0 | 0 | 2.25M | 662K |
| Deferred income tax benefit | 2.9M | 1.51M | 63K | 0 | 0 | 0 | 2.25M | 662K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 5.16M | -4.16M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 4.16M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 661K | 2.28M | 4.91M | 948K | 145K | 2.5M | -1.12M | 1.00M |
Cash generated by operating activities | -36.86M | -29.07M | -9.90M | -64.02M | -57.10M | -41.88M | -22.26M | -6.52M |
Investing activities | ||||||||
Purchases Of Investments | -57.42M | -61.68M | -45.30M | -95.73M | -144.37M | -84.04M | 0 | 0 |
Investments In Property Plant And Equipment | -110K | -139K | -33K | -400K | -3.06M | -7.67M | -2.19M | -139K |
Acquisitions Net | 0 | -175K | -1.23M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 20.25M | -59.81M | -33K | -10.63M | 1.53M | -91.70M | -2.19M | -139K |
Financing activities | ||||||||
Common Stock Issued | 72M | 2.90M | 89.60M | 67.73M | 62.29M | 93M | 71.48M | 13K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -88K | -213K | -107K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 133.57M | 96.67M | 14.91M | 67.73M | 62.29M | 142.14M | 71.48M | 10.71M |
Net Change In Cash | 116.96M | 7.78M | 4.97M | -6.91M | 6.72M | 8.55M | 47.02M | 4.04M |
Cash at end of period | 132.39M | 15.42M | 7.63M | 58.15M | 65.07M | 60.12M | 51.56M | 4.54M |
| Data source | Data source | Data source | Data source |